FDA recently lifted the partial hold placed on clinical trials evaluating Gilead’s magrolimab combined with azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)...
Moderna recently dosed the first patients in a Phase 1/2 study of its influenza mRNA vaccine candidates, mRNA-1020 and mRNA-1030.
The randomized, observer-blind trial will evaluate the safety,...
Eli Lilly & Company recently announced updates on the Phase 2 clinical trial studying its kinase inhibitor, Retevmo, in RET fusion-positive non-small cell lung cancer (NSCLC).
The...
Pfizer will acquire clinical-stage biopharmaceutical company ReViral to discover, develop, and commercialize novel antiviral respiratory syncytial virus (RSV) therapeutics.
ReViral’s...
Blue Care Network recently announced the launch of Michigan’s first end-to-end pharmacogenomics precision medicine program, Blue Cross Personalized Medicine. This program leverages genetic...
Sandoz recently expanded its strategic collaboration agreement with Ares Genetics (Ares) to drive cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
The...
Roche recently announced that its monoclonal IgG1 antibody, tiragolumab, plus Tecentriq and chemotherapy, did not meet its co-primary endpoints in a Phase 3 extensive-stage small cell lung cancer...
AstraZeneca recently announced that it will present new data underscoring its oncology treatment landscape through diverse early pipelines and novel drug combinations.
The company’s next...
Pfizer recently announced positive top-line results from a second Phase 3 study of its selective sphingosine 1-phosphate (S1P) receptor modulator, etrasimod, to treat moderately to severely active...
Pfizer recently announced that its selective sphingosine 1-phosphate (S1P) receptor modulator to treat moderate to severely active ulcerative colitis (UC) significantly improved the primary endpoint of...
Digital healthcare solutions company, Vivalink, will provide its Biometric Data Platform to help detect neutropenic fever events in oncology patients.
Vivalink is at the forefront of...
Thermo Fisher Scientific will invest $97 million to expand its clinical research operations in Virginia to support the increasing demand for drug development.
Over the next three years,...
Merck and the European Thoracic Oncology Platform (ETOP) recently announced that Keytruda significantly improved disease-free survival (DFS) in patients with stage IB to IIA non-small cell lung cancer...
Boehringer Ingelheim recently announced that the Phase 3 clinical trial studying empagliflozin in adults with chronic kidney disease (CKD) will stop early based on a recommendation from the trial's...
Moderna recently dosed the first participant in an HIV trimer mRNA vaccine (mRNA-1574) clinical trial.
The open-label Phase 1 trial will evaluate the safety and immunogenicity of...
Pfizer recently announced that a Clostridioides difficile (C. difficile) vaccine candidate did not meet its primary endpoint of C. difficile infection (CDI) prevention, but was 100- percent effective...
Novo Nordisk recently expanded its research collaboration in oral drug delivery technologies with the Massachusetts Institutes of Technology (MIT) and Brigham and Women’s Hospital...
Gilead recently announced that the Phase 3 clinical trial of Trodelvy in patients with HR/HER2-metastatic breast cancer met its primary endpoint.
The Phase 3 TROPiCS-02 study evaluated Trodelvy versus...
AstraZeneca Rare Disease and Alexion group recently closed a global collaboration and license agreement with Neurimmune AG for the investigational human monoclonal antibody, NI006.
NI006 is a...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently adopted a positive opinion for Pfizer and Biohaven’s generic drug to treat migraine...
